뒤로
Oramed Pharmaceuticals Inc(ORMP) 가격
ORMP 주가 차트
ORMP 수입
Oramed Pharmaceuticals Inc
$3.41
5.24%
$0.16
종가: Feb 06, 16:00:00 GMT-5
$3.41
0%
$0
애프터마켓: Feb 06, 20:00:00 GMT-5
최신 수익 결과: Q3 '25
보고됨: 2025-11-13
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
ORMP의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Oramed Pharmaceuticals Inc ORMP의 지난 분기 매출 실적은 어땠나요?
Oramed Pharmaceuticals Inc의 매출 추정치는 얼마인가요?
Oramed Pharmaceuticals Inc의 수익 품질 점수는 얼마인가요?
Oramed Pharmaceuticals Inc는 언제 수익을 보고하나요?
Oramed Pharmaceuticals Inc의 예상 수익은 얼마인가요?
Oramed Pharmaceuticals Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$3.24
시가
$3.28
일일 범위
$3.22 - $3.41
52주 범위
$1.82 - $3.71
거래량
166.8K
평균 거래량
248.0K
EPS(TTM)
1.74
배당수익률
--
시가총액
$135.7M
ORMP란 무엇인가요?
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2002-04-01. The firm has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. The company is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.